早期上皮性卵巢癌化学治疗现状与思考

Current chemotherapy research status and consideration of early-stage epithelial ovarian cancer

目前卵巢癌患者的死亡率,高居女性生殖系统恶性肿瘤患者的首位。卵巢癌的组织病理学类型复杂,其中上皮性卵巢癌(EOC)最为常见。但是,临床诊断的早期上皮性卵巢癌(EEOC)患者,仅占全部被诊断卵巢癌患者的30%。全面分期手术后,对高危EEOC患者的辅助化疗,是EEOC患者的标准治疗策略,但是辅助化疗方面,迄今尚有很多值得探讨的问题。笔者拟就EEOC患者术后辅助化疗研究现状,如患者化疗获益、化疗方案和化疗最佳时机选择、化疗疗程与淋巴切除问题的研究现状进行阐述,旨在为本病的规范化临床治疗提供参考。

Ovarian cancer is one of the most deadly malignancies of female reproductive system,with complex pathological types.The epithelial ovarian cancer(EOC)is the most common pathological type in ovarian cancer,but early-stage epithelial ovarian cancer(EEOC)only accounts for 30%in all diagnosed ovarian cancer.Adjuvant chemotherapy is the standard treatment strategy for high-risk EEOC patients after comprehensive staging surgery,but many issues are still worthy of discussion in adjuvant chemotherapy.We intend to clarify the current research status of postoperative adjuvant chemotherapy in patients with EEOC,such as the benefits of chemotherapy,the choice of chemotherapy regimen and the best timing for chemotherapy,the duration of chemotherapy and lymphadenectomy.We expect that this review can help providing references for standardized treatment of this disease.